The Clinical Trial Protocol by Na Tosha N Gatson, Shiao-Pei S Weathers and John F de Groot, entitled “ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma”, (CNS Oncology 5[1], 11–26 [2016]), has been retracted owing to the following:
In an effort to provide a detailed review of the ReACT Phase II clinical trial, the authors have provided data in a format that could be misinterpreted as a primary paper reporting the results of the trial. To this date, the original trial results are not currently published.
The authors and editors of CNS Oncology would like to sincerely apologize for any inconvenience this may have caused our readers and the investigators of the ReACT Phase II trial.